Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - REATA PHARMACEUTICALS INC | reta-ex322_9.htm |
| EX-32.1 - EX-32.1 - REATA PHARMACEUTICALS INC | reta-ex321_10.htm |
| EX-31.2 - EX-31.2 - REATA PHARMACEUTICALS INC | reta-ex312_11.htm |
| EX-31.1 - EX-31.1 - REATA PHARMACEUTICALS INC | reta-ex311_8.htm |
| EX-10.25 - EX-10.25 - REATA PHARMACEUTICALS INC | reta-ex1025_245.htm |
| 10-K - 10-K 2017 - REATA PHARMACEUTICALS INC | reta-10k_20171231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-3 No. 333-218915) and related prospectus,
(2)Registration Statement (Form S-8 No. 333-211682) pertaining to the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, and
(3)Registration Statement (Form S-8 No. 333-216412) pertaining to the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan;
of our report dated March 2, 2018, with respect to the consolidated financial statements of Reata Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Dallas, Texas
March 2, 2018